Corbus Pharmaceuticals Holdings Inc Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corporate Call Transcript
Hello, and welcome to the Corbus Pharmaceuticals Conference Call. (Operator Instructions) This conference is being recorded at the company's request and will be available at the company's website approximately 2 hours following the end of the call.
I would now like to turn the call to your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Please go ahead, sir.
Thank you, operator. Good morning, everyone. At this time, I'd like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations or projections of the future. These are forward-looking statements that involve risks and uncertainties.
Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws.
These forward-looking statements are based on Corbus' current expectations and actual results could differ materially. As a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |